Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

Focusing on patient to create relevant and lasting apps

105 vues

Publié le

Hiboot is an app designed to help over 600 000 chronic disease patients daily. Discover our conference at the International Digital Health Congress Doctors 2.0 explaining our approach to creating relevant and lasting apps by focusing on patients

Publié dans : Santé
  • Soyez le premier à commenter

  • Soyez le premier à aimer ceci

Focusing on patient to create relevant and lasting apps

  1. 1. Focusing on patient to create relevant and lasting apps. J.SELLAM & H.JEANTET
  2. 2. Jeremie Sellam Professor of Rheumatology, AP-HP Saint-Antoine hospital Pierre & Marie Curie University Patient care and clinical/biological research on rheumatic diseases Henri Jeantet Co-founder @ unknowns, an innovation studio & consultancy with a strong commitment to social sciences. Who we are
  3. 3. _Core metrics to look at : Download User retention Usage Impact on real life ! How to create relevant and lasting apps ?
  4. 4. Our vision: from disease to people There is a gap between the wealth of scientific knowledge about diseases/treatments and the knowledge of patients’ daily lives, their issues and behaviors regarding their health. Technology can bridge this gap, if and only if it is build around and with people.
  5. 5. Rheumatoid arthritis • 300,000 patients in France • beginning 40-60 years old • Auto-immune disease with joint inflammation • Progressive joint pain, destruction and functional disability • Chronic disease Þlong term treatment Spondyloarthritis • 300,000 patients in France • beginning 30-40 years old • Back pain, arthritis, heel pain • Association with psoriasis or colitis • Chronic disease Þlong term treatment What diseases are we talking about ?
  6. 6. Rheumatoid arthritis Spondyloarthritis What diseases are we talking about ? Early RA Established RA (too) late RA
  7. 7. • Specific blockade of inflammation pathways (TNF, IL-6, T-cells, B-cells) • Prevention of joint destruction The era of targeted biotherapies since 2000 : a revolution for the patient and for the rheumatologist van Vollenhoven, R. F. Nat. Rev. Rheumatol 2009
  8. 8. Immunosuppressive drugsÞ­risk of infection
  9. 9. Our starting point : safety Our objective : How do we enhance biotherapies safety, a self-administred immunosuppressive drug ? Our assumption : Reassuring people through a checklist would increase patient compliance.
  10. 10. #1 Understanding people.
  11. 11. Understanding behaviors : method Quantitative study (in collaboration with patient’s association) : - online study, 330 respondents Ethnography : - led by a anthropologist, 21 respondents.
  12. 12. « It’s not a disease, but a chronic problem. I have a body with specific needs » You don’t catch them, You can’t really cure them You have to live with them through a career. #1 Chronic diseases are different
  13. 13. #2 An ideal of normal life A desire for normality that relies on autonomy at three levels : Doctor-patient relationship Building a more equal relationship based on a common knowledge, in which the patient is part of the solution. Skills and Knowledge Coordination Information Collaboration Experimentation Adaptation Treatment appropriation Managing the treatment Building habits & rituals Experience
  14. 14. #3 a fundamental tension Habits and rituals are good for compliance… …but they lead to trivialization and overconfidence… ...and increases risks of infection.
  15. 15. The design challenge : How do we build a tool that helps people live better, so that they would integrate the checklist in their ritual and stop being overconfident ?
  16. 16. #2 Here comes Hiboot.
  17. 17. All those insights are the foundations of the user experience. Building from people’s lives.
  18. 18. Answer real question in a real non-medical language : a situational Q&A built around daily life (trip, vaccine, fever, dentist, etc.) Personalized according to the treatment of the user Help patient gain more autonomy
  19. 19. Help keep track of life with the disease (people forget) Don’t be medical Help patient get a better life
  20. 20. Be a useful companion Make the checklist part of the ritual Integrate the ritual
  21. 21. In order to reinforce usages across different type of users, we will multiply features that helps patients daily lives. And more to come
  22. 22. #3 Main learnings.
  23. 23. « what do they do/live now ? what will they do/live tomorrow? » Building an app/a website/IOT is not a goal, it’s a way to help patients achieve something. Have a clear objective
  24. 24. Doctors and professionals are irrational people too. Healthcare is still dominated by a top-down culture Engaging patient from the beginning is key to relevance. Doctors and pharma don’t always really know patient’s lives.
  25. 25. Go fast for real life, even with an imperfect product, as this is the only way to improve it. Be ready to change everything from user’s feedback. And factor it into your financial approach : the 1-1/2 rule Getting online is the beginning
  26. 26. Put needs first, define what is your design challenge, and then decide what kind of technology you need. Problem first, technology second
  27. 27. Try to avoid it at first, in order to go fast. Once tested, tried and proven, you’ll have the data to justify the investment. Medical device regulation are a pain.
  28. 28. Rely on existing, verified and accepted and validated recommendations (Club Rhumatismes Inflammation): just re-write them with people in mind Rely on scientific society to be the product’s face : it helps engage all stakeholders Build a neutral ground
  29. 29. Gives credibility Helps acceptance Generates referrals Helps with the work Provide insights Engaging stakeholders is key to success Pharma companies Patient Associations Doctors Hospitals Scientific Society Patients Scientific board Pr J. SELLAM Pr T. PHAM Dr C. BEAUVAIS Pr F. TUBACH
  30. 30. Thanks !